pharma · Pulmonary Arterial Hypertension · Iron Deficiency Anemia · KROS
Keros Therapeutics
K2B Therapeutics is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker KROS. Primary therapeutic focus areas include Pulmonary Arterial Hypertension, Iron Deficiency Anemia. NovaPharmaN
Cambridge, USA HQ
2021 Founded
10 Employees
Public company Type
KROS · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2021
- Employees
- 10
- Programs
- 3
- Drugs
- 2
- Patents
- 12
KER-047
Phase 2 · small molecule · Iron Deficiency Anemia
KER-047 for Iron Deficiency Anemia is a Phase 2 program (small_molecule) at Keros Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code KER047-IR-202
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Keros Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Iron Deficiency Anemia
- Status
- terminated
- Trials
- 1